Granules India's net profit up 26 pc to Rs 41 cr in Q2

MUMBAI: Pharmaceutical firm Granules India today announced 26 per cent jump in net profit at Rs 41 crore in the quarter ended September 30 as compared to Rs 32 crore in the corresponding period a year ago.

The company's revenue increased by 3 per cent at Rs 364 crore as compared to Rs 353 crore in the corresponding period, a company statement said here.

"We are focused to achieve our long-term goals as we move ahead in the investment phase. Our API and PFI capacity enhancements within our base business and Greenfield API facility in Vizag are both on track," Granules India Chairman & Managing Director Krishna Prasad Chigurupati said.

"In addition, our product development and subsequent filing continues to make steady progress. During the quarter, the US FDA approved our ANDA for Ibuprofen 200 mg orange tablets which enhances our product portfolio," Chigurupati added.